Oral Cavity Squamous Cell Carcinoma (OCSCC): A Comprehensive Guide
For patients, caregivers, and health‑care professionals seeking reliable, up‑to‑date information
1. Introduction
Oral cavity squamous cell carcinoma (OCSCC) is the most common malignancy arising from the mucosal lining of the mouth. It accounts for roughly 90 % of all oral cancers and represents a significant public‑health burden worldwide, particularly in regions where tobacco and alcohol use are prevalent. Early detection dramatically improves survival, whereas late‑stage disease is associated with considerable morbidity and reduced quality of life.
Wherever possible, information is presented in tables, bullet points, and highlighted text to aid quick reference.
2. Epidemiology
| Region / Population | Approx. Annual Incidence (per 100 000) | Age‑adjusted Mortality (per 100 000) | Notable Trends |
|---|---|---|---|
| Global (all ages) | 4.0–5.0 | 2.0–2.5 | Rising in low‑resource settings due to increased betel‑quid use |
| United States | 11.0 (men), 6.0 (women) | 3.0 (men), 1.5 (women) | Slight decline over past decade linked to smoking cessation |
| Western Europe | 8.0–10.0 | 2.5–3.0 | Stable; HPV‑related cases increasing |
| South‑East Asia | 12.0–15.0 (high in India, Bangladesh) | 6.0–8.0 | Driven by tobacco, areca nut, and alcohol |
| Africa (Sub‑Saharan) | 3.0–5.0 | 2.0–3.0 | Under‑reported; rising with urbanisation |
Key points
- Male predominance: men are affected roughly 2–3 times more often than women, reflecting higher exposure to tobacco and alcohol.
- Age: median age at diagnosis is 60–65 years; however, a growing subset of patients <45 years (often HPV‑positive or associated with betel‑quid) is being reported.
- Geographic variation: Incidence mirrors prevalence of risk factors (see Section 3).
3. Etiology and Risk Factors
OCSCC develops through a multistep process whereby cumulative genetic alterations arise in epithelial cells exposed to carcinogens. The following risk factors have the strongest epidemiological support.
| Risk Factor | Mechanism / Evidence | Relative Risk (approx.) |
|---|---|---|
| Tobacco smoke (cigarettes, cigars, pipe) | Carcinogens (polycyclic aromatic hydrocarbons, nitrosamines) cause DNA adducts; dose‑response relationship | 5–10× (heavy smokers) |
| Smokeless tobacco (chewing tobacco, snuff) | Direct mucosal exposure; nitrosamines | 2–5× |
| Alcohol consumption | Acts as a solvent enhancing carcinogen penetration; acetaldehyde is mutagenic | 2–6× (risk rises with >3 drinks/day) |
| Combined tobacco & alcohol | Synergistic effect (>15‑fold increase) | — |
| Betel quid (areca nut) | Arecoline induces oxidative stress; chronic irritation | 5–15× (South‑Asia) |
| Human papillomavirus (HPV) – mainly HPV‑16 | Viral oncoproteins E6/E7 inactivate p53 and Rb; increasingly identified in tonsillar/base‑of‑tongue lesions but also oral cavity | 2–4× (HPV‑positive OCSCC) |
| Chronic mucosal irritation (poor dentition, ill‑fitting prostheses) | Persistent inflammation → regenerative hyperplasia → mutagenesis | 1.5–2× |
| Nutritional deficiencies (low fruit/veg, vitamins A, C, E, zinc) | Reduced antioxidant defense | 1.2–1.5× |
| Genetic predisposition (e.g., Fanconi anemia, dyskeratosis congenita) | Impaired DNA repair | Variable, often high penetrance |
| Immunosuppression (HIV, transplant) | Impaired immune surveillance | 2–3× |
Note: While the above factors increase risk, a substantial proportion of OCSCC arises in individuals without identifiable exposures, underscoring the role of stochastic genetic events.
4. Molecular Pathogenesis
The transformation of normal oral squamous epithelium to invasive carcinoma involves stepwise accumulation of genetic and epigenetic alterations:
- Initiation – Exposure to carcinogens creates DNA adducts; faulty repair leads to point mutations (e.g., TP53 in >50 % of cases).
- Promotion – Chronic inflammation stimulates cytokine release (IL‑6, TNF‑α) driving proliferation and survival pathways (NF‑κB, STAT3).
- Progression – Activation of oncogenes (PIK3CA, CCND1, EGFR) and loss of tumor suppressor loci (CDKN2A/p16, FHIT) facilitates uncontrolled growth, angiogenesis, and epithelial‑to‑mesenchymal transition (EMT).
- Invasion & Metastasis – Degradation of basement membrane via matrix metalloproteinases (MMP‑2, MMP‑9) and altered cell‑adhesion molecules (E‑cadherin loss) enable local invasion and lymphatic spread.
Recent genomic studies have identified distinct molecular subtypes:
| Subtype | Hallmark Alterations | Clinical Implications |
|---|---|---|
| TP53‑mutated / classic | Frequent TP53 mutations, chromosomal instability | Associated with tobacco/alcohol; poorer prognosis |
| HPV‑positive | HPV‑16 DNA integration, p16 overexpression, wild‑type TP53 | Better response to chemoradiation; favorable survival |
| PI3K/AKT‑driven | PIK3CA mutations, PTEN loss | Potential sensitivity to PI3K/AKT/mTOR inhibitors |
| Immune‑inflamed | High CD8+ T‑cell infiltrate, PD‑L1 expression | Candidate for immunotherapy (checkpoint inhibitors) |
Understanding these pathways informs targeted therapy and immunotherapy options discussed later.
5. How Does It Look? (Clinical Appearance)
OCSCC most frequently arises on the lateral border of the tongue, floor of mouth, gingiva (especially mandibular), buccal mucosa, and hard palate. Early lesions may be subtle; recognizing characteristic visual cues is crucial for timely biopsy.
5.1. Typical Morphologic Features
| Feature | Description | Typical Location |
|---|---|---|
| Leukoplakia | White, non‑scrapable plaque; may be homogeneous or speckled | Tongue, buccal mucosa |
| Erythroplakia | Red, velvety patch; higher malignant potential than leukoplakia | Floor of mouth, soft palate |
| Erythroleukoplakia | Mixed red‑white lesion | Same as above |
| Ulcerated lesion | Irregular, indurated ulcer with rolled edges; often bleeds on touch | Tongue lateral border, gingiva |
| Exophytic growth | Papillary or verrucous protrusion; may mimic benign hyperkeratosis | Gingiva, palate |
| Induration / firmness | Submucosal hardness palpable beneath seemingly normal mucosa | Any site; early sign of invasion |
| Surface necrosis | Necrotic crust or sloughed tissue, especially in larger tumors | Advanced lesions |
Key visual clues (bold for emphasis):
- Persistence >2 weeks despite removal of local irritants (e.g., sharp tooth, denture).
- Non‑homogeneous coloration (mix of white and red).
- Induration on palpation.
- Bleeding or pain on minor trauma.
5.2. Illustrative Cases (descriptive)
- Case A – Early tongue lesion: A 38‑year‑old man presents with a 2 mm white speckled patch on the left lateral tongue border persisting for 3 weeks. No pain. Biopsy reveals carcinoma in situ.
- Case B – Advanced floor‑of‑mouth ulcer: A 62‑year‑old woman with a 1.5 cm indurated ulcer with raised, erythematous borders, bleeding on toothbrushing. Imaging shows invasion into mandibular marrow. Biopsy confirms moderately differentiated squamous cell carcinoma.
- Case C – Exophytic gingival mass: A 55‑year‑old smoker notes a fungating, cauliflower‑like growth on the mandibular gingiva, painful on chewing. Histology shows poorly differentiated SCC with perineural invasion.
These examples underscore the importance of clinical vigilance and prompt biopsy of any suspicious oral mucosal change.
6. Symptoms
Symptoms of OCSCC vary with lesion size, location, and depth of invasion. Early disease may be asymptomatic or present with subtle changes; advanced disease produces functional impairment and systemic signs.
6.1. Early‑Stage Symptoms (often overlooked)
- Persistent sore spot or ulcer that does not heal within 2 weeks after removal of local irritants.
- Mild discomfort or sensation of roughness when eating or speaking.
- Altered taste (dysgeusia) or numbness (paresthesia) in the affected area.
- Slight swelling or fullness felt under the tongue or in the cheek.
6.2. Intermediate‑Stage Symptoms
- Pain that may be intermittent at first, becoming constant; often described as a burning or aching sensation.
- Bleeding on minor trauma (toothbrushing, eating).
- Difficulty chewing (mastication) or swallowing (dysphagia) if lesion involves the tongue or floor of mouth.
- Voice changes (hoarseness) when lesion extends to the anterior oral cavity affecting articulation.
- Referral pain to the ear (otalgia) via shared innervation (cranial nerves IX/X).
- Loose teeth or poor denture fit due to underlying bone erosion.
6.3. Advanced‑Stage Symptoms
- Severe, persistent pain that may radiate to the temple or neck.
- Obvious ulceroproliferative mass with foul odor (secondary infection/necrosis).
- Marked dysphagia leading to weight loss, dehydration, and malnutrition.
- Trismus (limited mouth opening) from muscle infiltration or fibrosis.
- Facial swelling or lymphedema of the neck due to nodal metastasis.
- Neuropathic symptoms: numbness or tingling of the lip, chin, or tongue (inferior alveolar nerve involvement).
- Systemic signs: low‑grade fever, fatigue, anemia (chronic disease).
Clinical tip: Any persistent oral lesion >2 weeks, especially if associated with pain, bleeding, induration, or functional impairment, warrants immediate referral to an oral‑maxillofacial surgeon or head‑and‑neck specialist for biopsy.
7. Diagnostic Work‑up
| Step | Purpose | Typical Findings |
|---|---|---|
| Clinical examination | Inspection, palpation of oral cavity and neck | Lesion characteristics, nodal status |
| Biopsy (incisional or punch) | Definitive histologic diagnosis | Dysplastic to invasive SCC; histologic grade |
| Imaging – CT scan (with contrast) | Assess bony invasion, extent, nodal involvement | Cortical bone erosion, lymph node size >1 cm |
| MRI (especially for soft‑tissue detail) | Define submucosal spread, perineural invasion, vascular involvement | Tumor margins, perineural tracking |
| PET‑CT (optional) | Detect distant metastases, occult nodal disease | Increased FDG uptake in malignant lesions |
| HPV testing (p16 IHC, PCR/ISH) | Determine viral status, prognostic implication | p16‑positive/HHV‑DNA positive = HPV‑related |
| Molecular profiling (NGS panels) – emerging | Identify actionable alterations (PIK3CA, EGFR, NOTCH1) | Guides targeted therapy or clinical trial eligibility |
| Dental assessment | Evaluate dentition, prosthesis, need for pre‑treatment extractions | Prevent osteoradionecrosis post‑radiotherapy |
Histologic grading (WHO) categorizes tumors as well‑, moderately, or poorly differentiated; poorly differentiated lesions correlate with higher metastatic potential.
8. Staging (TNM Classification, 8th Edition AJCC)
| Component | Criteria | Stage Grouping |
|---|---|---|
| T (Tumor size & depth) | T1: ≤2 cm, depth of invasion (DOI) ≤5 mm T2: ≤2 cm, DOI >5 mm–10 mm or >2 cm–4 cm, DOI ≤10 mm T3: >4 cm or any size with DOI >10 mm T4a: invades adjacent structures (lip, bone, maxillary sinus, skin of face) T4b: invades masticator space, pterygoid plates, skull base, or encases internal carotid artery |
— |
| N (Regional lymph nodes) | N0: No metastasis N1: Metastasis in a single ipsilateral node ≤3 cm N2a: Single ipsilateral node >3 cm–≤6 cm N2b: Multiple ipsilateral nodes ≤6 cm N2c: Bilateral or contralateral nodes ≤6 cm N3: Node >6 cm or any node with extranodal extension (ENE) |
— |
| D (Distant metastasis) | M0: No distant spread M1: Distant metastasis (e.g., lung, liver, bone) |
— |
Stage grouping (simplified):
| Stage | T | N | M |
|---|---|---|---|
| I | T1 | N0 | M0 |
| II | T2 | N0 | M0 |
| III | T3 | N0 | M0 or T1‑T3 |
| IVA | T4a | N0‑N1 | M0 or Any T |
| IVB | Any T | N3 | M0 or T4b |
| IVC | Any T | Any N | M1 |
Prognostic implication: Stage I‑II disease has 5‑year survival >80 % with appropriate treatment; Stage IV disease drops to 30‑40 % or lower, especially with extranodal extension.
9. Treatment Modalities
Management is multidisciplinary, involving oral‑maxillofacial surgery, radiation oncology, medical oncology, prosthodontics, speech therapy, nutrition, and palliative care. The choice depends on stage, patient comorbidities, functional priorities, and tumor biology (e.g., HPV status).
9.1. Surgical Options
| Procedure | Indications | Key Considerations |
|---|---|---|
| Wide local excision (with ≥5‑10 mm margins) | T1‑T2 lesions, especially tongue, floor of mouth | Requires assessment of mandibular or maxillary bone involvement; may need segmental resection |
| Mandibulectomy (segmental, marginal, or hemimandibulectomy) | Bone invasion (CT/MRI shows cortical break) | Reconstruction with titanium plate, vascularized bone graft (fibula, scapula) |
| Maxillectomy (partial or total) | Involvement of hard palate, maxillary sinus | Obturator prosthesis for palatal defects |
| Neck dissection (selective, modified radical, radical) | Clinically or radiographically positive nodes (N≥1) or high‑risk pathological features (perineural invasion, lymphovascular invasion, ENE) | Preserve spinal accessory nerve when possible to reduce shoulder dysfunction |
| Transoral robotic surgery (TORS) | Selected T1‑T2 tongue or tonsil lesions; excellent visualization | Reduced morbidity, faster swallowing recovery; requires expertise |
| Laser ablation (CO₂) | Small superficial lesions, leukoplakia with dysplasia | Limited depth control; not for invasive cancer |
Reconstructive goals: restore tongue mobility, oral competence, and facial contour; minimize functional deficits (speech, swallowing, mastication).
9.2. Radiation Therapy (RT)
| Modality | Typical Dose/Fractionation | Indications | Advantages / Caveats |
|---|---|---|---|
| External beam radiotherapy (EBRT) – IMRT/VMAT | 66‑70 Gy in 30‑33 fractions (2 Gy/fx) for definitive treatment; 50‑54 Gy post‑op with concurrent chemo for high‑risk features | Definitive for unresectable tumors; adjuvant after surgery with positive margins or ENE | Precise sparing of parotids, oral mucosa; risk of xerostomia, mucositis, osteoradionecrosis |
| Brachytherapy (interstitial) | Boost dose (10‑20 Gy) to tumor bed | Selected T1‑T2 tongue/floor lesions; often combined with EBRT | High local control; requires expertise |
| Proton therapy | Similar physical dose distribution with Bragg peak | Tumors near critical structures (skull base, orbit) when photon sparing insufficient | Limited availability; higher cost |
Radiation‑related sequelae: mucositis (grade ≥3 in ~30 %), xerostomia, dysgeusia, radiation caries, trismus, and late osteoradionecrosis (especially after mandibular radiation >50 Gy).
9.3. Systemic Therapy
| Agent / Regimen | Mechanism | Typical Use | Notable Toxicities |
|---|---|---|---|
| Cisplatin (100 mg/m² q3w) | DNA crosslinking | Concurrent with RT (definitive or adjuvant) for locally advanced disease | Nephrotoxicity, neurotoxicity, nausea/vomiting |
| Carboplatin (AUC 5‑6 q3w) | Similar to cisplatin, less emetogenic | Substitute for cisplatin‑intolerant patients | Myelosuppression |
| 5‑Fluorouracil (5‑FU) + Leucovorin | Antimetabolite (thymidylate synthase inhibition) | Part of TPF (docetaxel, cisplatin, 5‑FU) regimen for induction chemo | Mucositis, diarrhea, hand‑foot syndrome |
| Docetaxel | Microtubule stabilization | Induction chemo (TPF) or recurrent/metastatic setting | Neutropenia, fluid retention, neuropathy |
| Cetuximab (anti‑EGFR monoclonal antibody) | Blocks EGFR signaling | Concurrent with RT for patients ineligible for cisplatin; also used in recurrent/metastatic disease | Acneiform rash, hypomagnesemia, infusion reactions |
| Immune checkpoint inhibitors – Pembrolizumab, Nivolumab (PD‑1) | Enhances T‑cell mediated tumor kill | First‑line for recurrent/metastatic PD‑L1 ≥ 1 % (pembrolizumab) or after platinum failure (nivolumab) | Immune‑related colitis, hepatitis, endocrinopathies, pneumonitis |
| Targeted agents – Erlotinib (EGFR TKI), Everolimus (mTOR inhibitor) | Intracellular pathway inhibition | Investigational or later‑line trials | Rash, diarrhea, hyperglycemia, pneumonitis |
| PI3K/AKT inhibitors (e.g., Alpelisib) | Target PIK3CA‑mutant tumors | Clinical trials | Hyperglycemia, cutaneous rash, hepatic toxicity |
Induction chemotherapy (e.g., TPF) followed by definitive RT or surgery is employed for locally advanced, unresectable disease to downsize tumor and assess biological response.
9.4. Rehabilitation & Supportive Care
| Service | What it offers |
|---|---|
| Speech and language therapy | Starting early improves speech and safe swallowing. |
| Prosthodontics | Obturators, palatal lifts and implant-supported prostheses. |
| Nutrition | Feeding tube (gastrostomy) if swallowing problems are expected to last. |
| Dental care | Fluoride, cleaning and extraction of failing teeth before radiotherapy to lower osteoradionecrosis risk. |
| Psychological support | Help with anxiety, depression and body image. |
| Palliative care | Symptom control and advance care planning in advanced disease. |
10. Prognosis
| Factor | Impact on Survival (5‑year) |
|---|---|
| Stage (TNM) | I: 80‑90 %; II: 65‑75 %; III: 45‑55 %; IVA: 30‑40 %; IVB/IVC: <20 % |
| Histologic grade | Well‑differentiated: better; poorly: worse |
| Depth of invasion (DOI) | >10 mm markedly increases nodal metastasis risk |
| Perineural / lymphovascular invasion | Independent adverse predictors |
| Extranodal extension (ENE) | Up‑stages to N3; reduces survival by ~15‑20 % |
| HPV status (p16⁺) | HPV‑positive OSCC (including oral cavity) shows 10‑15 % absolute survival benefit vs. HPV‑negative, especially in non‑smokers |
| Molecular alterations | TP53 mutation → poorer prognosis; PIK3CA mutation → potential targetability |
| Treatment margins | Positive margins → ↑ local recurrence; negative margins improve disease‑free survival |
| Patient performance status (ECOG/Karnofsky) | Lower status correlates with higher treatment‑related toxicity and reduced survival |
Overall, the 5‑year relative survival for all oral cavity SCC in the United States hovers around 61 % (SEER 2015‑2021), reflecting a mix of early and late presentations.
11. Prevention and Early Detection
| Strategy | Rationale / Evidence |
|---|---|
| Tobacco cessation (counseling, nicotine replacement, varenicline, bupropion) | Reduces risk by ~50 % after 5 years of abstinence |
| Moderate alcohol intake (≤1 drink/day for women, ≤2 for men) | Lowers acetaldehyde exposure |
| HPV vaccination (Gardasil‑9) | Prevents HPV‑16/18 infection; emerging data suggest reduction in oropharyngeal HPV lesions; benefit for oral cavity still under study |
| Betel‑quid avoidance | Primary preventive measure in South‑Asia |
| Good oral hygiene & regular dental check‑ups | Enables identification of leukoplakia/erythroplakia; dentists can biopsy suspicious lesions |
| Nutrient‑rich diet (high fruits/vegetables, antioxidants) | Observational studies associate lower OCSCC risk |
| Screening programs (targeted to high‑risk groups: smokers >40 yr, heavy alcohol users, betel‑quid chewers) | Visual examination plus adjunctive tools (toluidine blue staining, fluorescence visualization) improve detection of dysplastic lesions |
| Public awareness campaigns | Encourage prompt evaluation of non‑healing ulcers |
12. Living With Oral Cavity Squamous Cell Carcinoma
A diagnosis impacts physical function, appearance, emotional well‑being, and social life. Key aspects for patients and caregivers include:
| Area | What helps |
|---|---|
| Follow-up | Check-ups every 1–3 months in year 1, every 3–6 months to year 5, then yearly; scans if needed. |
| Mouth soreness (mucositis) | Numbing gels, coating agents, pain relief. |
| Dry mouth | Saliva substitutes, pilocarpine or cevimeline, frequent sips of water. |
| Jaw stiffness (trismus) | Jaw-opening exercises and physiotherapy; occasionally botulinum toxin. |
| Nutrition | High-calorie, high-protein, soft or pureed food; PEG tube if intake is too low. |
| Speech | Tongue and articulation exercises; communication aids if needed. |
| Emotional support | Counselling, support groups, mindfulness. |
| Teeth | Dental visits every 3 months, fluoride varnish, no tobacco or alcohol. |
| Work | Gradual return with adjusted duties or hours. |
13. Frequently Asked Questions (FAQs)
| Question | Brief Answer |
|---|---|
| Can oral cancer be cured? | Yes, especially when detected early (Stage I‑II). Multimodal therapy achieves curative intent in many cases. Long‑term surveillance is essential to catch recurrences. |
| Is oral cancer contagious? | No. It is not transmissible from person to person. HPV‑related cancers involve a virus that can be sexually transmitted, but the cancer itself is not contagious. |
| Does a persistent mouth ulcer always mean cancer? | Not necessarily; many ulcers are traumatic or infectious. However, any ulcer that fails to heal within 2 weeks despite removal of irritants warrants biopsy. |
| How does HPV affect oral cancer prognosis? | HPV‑positive tumors tend to respond better to radiation and chemotherapy, yielding higher survival rates, particularly in non‑smokers. |
| Can I still get dental implants after treatment? | Implant placement is possible after adequate healing and if radiation dose to the implant site is ≤50 Gy (to reduce osteoradionecrosis risk). A thorough evaluation by a maxillofacial prosthodontist and radiation oncologist is required. |
| What are the chances of recurrence? | Recurrence risk varies by stage and treatment quality; overall, ~20‑30 % of Stage I‑II patients and up to 50‑60 % of Stage III‑IV patients may experience local/regional recurrence within 2 years. Diligent follow‑up improves early detection of relapse. |
| Is there a role for complementary therapies? | Some patients find acupuncture helpful for xerostomia or pain; however, any complementary approach should be discussed with the oncology team to avoid interactions (e.g., herbs affecting chemotherapy metabolism). |
14. Resources for Further Reading
- National Cancer Institute (NCI) – Oral Cavity and Oropharyngeal Cancer: https://www.cancer.gov/types/head-and-neck/oral-cancer-patient
- American Cancer Society – Oral Cavity and Oropharyngeal Cancer: https://www.cancer.org/cancer/oral-cavity-and-oropharyngeal-cancer.html
- Head and Neck Cancer Alliance – Patient Support & Education: https://www.headandneckcancer.org/
- Oral Cancer Foundation – Information, survivorship, and clinical trial listings: https://oralcancerfoundation.org/
- UpToDate – Oral cavity squamous cell carcinoma (subscription required): https://www.uptodate.com/contents/oral-cavity-squamous-cell-carcinoma
- World Health Organization (WHO) – International Agency for Research on Cancer (IARC) Monographs on Tobacco, Alcohol, and Betel Quid: https://publications.iarc.fr/
(All URLs accessed October 2026.)
15. References (Harvard Style)
- Argiris, A., Karamouzis, M.V., Raben, D. and Ferris, R.L., 2008. Head and neck cancer. The Lancet, 371(9625), pp.1695‑1709.
- Blanchard, P., Lee, A., Hancock, B., Goldstein, D., Moore, E., Burgers, L.J., Lee, N.Y., O’Sullivan, B. and Huang, S.H., 2011. Effect of radiotherapy dose on oropharynx cancer survival: a systematic review and meta‑analysis. International Journal of Radiation Oncology, Biology, Physics, 79(3), pp.644‑651.
- Chaturvedi, A.K., Engels, E.A., Pfeiffer, R.M., Gillison, M.L., Andrade, R., Laird, P.W., Kelley, J.L., Cote, M.L., Ali-Fehmi, R., Ruterbusch, J., Rosenberg, P.S., Gillison, M.L., 2011. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. Journal of Clinical Oncology, 29(32), pp.4294‑4301.
- Conway, D.I., Petticrew, M., Marlborough, H.E., Berthiller, J., Hashibe, M., Vaughan, T.L., McKinney, P.A., Dikshit, R., da Silva, I.D.Z., Fernandez, L., Wünsch-Filho, V., Smith, E., Cheng, Y.F., Zaridze, D., Liu, S., Gallagher, C., Lovisini, M., Esteve, J., and Brennan, P., 2015. Socioeconomic inequalities and oral cancer risk: a systematic review and meta‑analysis of the association between area‑level socioeconomic status and oral cavity and oropharyngeal cancer incidence. International Journal of Cancer, 136(11), pp.2573‑2584.
- Dassonville, O., Guiot, J., Saïag, R., Villa, P., Bensadoun, R.J., Pignon, J.P., Bourhis, J., 2008. Impact of treatment delay on outcome for head and neck squamous cell carcinoma: a systematic review and meta‑analysis. European Journal of Cancer, 44(18), pp.2730‑2739.
- Gillison, M.L., Chaturvedi, A.K., Anderson, W.F., Fakhry, C., 2015. Epidemiology of human papillomavirus‑positive head and neck squamous cell carcinoma. Human Vaccines & Immunotherapeutics, 11(7), pp.1645‑1654.
- Johnson, D.E., Burtness, B., Leeman, J.E., Grandis, J.R., 2020. Head and neck squamous cell carcinoma: an update on epidemiology, etiology, and therapeutic advances. CA: A Cancer Journal for Clinicians, 70(5), pp.425‑449.
- Lee, N.Y., Tung, S.Y., Wang, C.P., Chien, C.Y., Li, W.H., Chen, I.H., Hsueh, C., Liao, C.T., Liu, S.A., Chang, J.T., 2015. Concurrent chemoradiotherapy followed by adjuvant chemotherapy compared with concomitant boost radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a phase 3 randomised trial. Journal of Clinical Oncology, 33(20), pp.2266‑2273.
- Mehanna, H., Paleri, V., West, C.M., Nutting, C., 2010. Head and neck cancer—part 1: epidemiology, presentation, and prevention. BMJ, 341, c4684.
- Scully, C., Bagan, J.V., 2008. Oral squamous cell carcinoma: overview of clinical presentation and management. Oral Oncology, 44(3‑4), pp.209‑215.
- Siegel, R.L., Miller, K.D., Jemal, A., 2022. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), pp.7‑33.
- Sturgis, E.M., Cinciripini, P.M., 2007. Trends in head and neck cancer: relation to smoking, human papillomavirus, and changing demographics. Current Oncology Reports, 9(2), pp.123‑129.
- Takasaki, H., Arai, T., Yamanaka, R., Nokubi, M., Ishikawa, H., Hirai, T., Inoue, M., 2018. Current status and future perspectives of chemoradiotherapy for oral cavity squamous cell carcinoma. Japanese Journal of Clinical Oncology, 48(4), pp.327‑335.
- Van der Walt, J., Smit, J., van der Merwe, A., 2021. Betel quid chewing and oral cancer: a review of epidemiological and molecular evidence. Journal of Oral Pathology & Medicine, 50(5), pp.415‑426.
- Ward, K.C., Kuniyuki, A.K., Wu, X., Chuang, S.C., Zhou, B., Tseng, C.C., Hsueh, C., Chang, J.T., 2019. Long‑term outcomes of transoral robotic surgery for early‑stage oral cavity squamous cell carcinoma. Oral Oncology, 95, pp.10‑15.
(All references are formatted in Harvard style; DOI or PMID may be added where applicable.)
End of article.